Testosterone therapy and mortality risk

Endogenous testosterone and mortality risk

In men, obesity and metabolic complications are associated with lower serum testosterone (T) and dihydrotestosterone (DHT) and an increased risk of, and mortality from, multiple chronic diseases in addition to cardiovascular disease (CVD). The causal interrelationships between these factors remain a matter of debate. In men with untreated congenital and lifelong forms of hypogonadotropic hypogo...

Testosterone therapy and cardiovascular risk.

Endogenous testosterone levels are inversely associated with cardiovascular risk in older men and men with cardiovascular disease. Current data on cardiovascular outcomes of testosterone therapy include only observational studies and adverse event monitoring in short-term trials that were not designed to measure cardiovascular outcomes. These studies have yielded conflicting results, and some h...

Testosterone therapy and mortality in US veterans.

hether lower testosterone levels are a causal factor or biomarker for disease in older men remains fiercely debated, as randomized controlled trials with endpoints of cardiovascular events or mortality are lacking. Here, a recent retrospective study in US veterans is discussed, which compares mortality rates in men who were and were not prescribed testosterone. As men grow older, endogenous tes...

Conclusions about testosterone therapy and cardiovascular risk

Postmenopausal testosterone therapy and breast cancer risk.

BACKGROUND Testosterone therapy is being increasingly used in the management of postmenopausal women. However, as clinical trials have demonstrated a significantly increased risk of breast cancer with oral combined estrogen-progestin therapy, there is a need to ascertain the risk of including testosterone in such regimens. OBJECTIVE Evaluation of experimental and epidemiological studies perta...